| Date | Title | Description |
| 22.10.2024 | Terray Therapeutics: $120 Million (Series B) Secured To Improve Human Health | Terray Therapeutics, a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced Series B fu... |
| 09.10.2024 | City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine | City Therapeutics announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. And City Therapeutics aims to utilize next-generation engineering of small interfering RNAs (siRNAs) – which is the “trigger”... |
| 19.09.2024 | 3 Genomics Stocks Transforming Healthcare Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investin... | Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals (REGN), Al... |
| 03.09.2024 | ProofPilot Bolsters Advisory Board with Appointment of Michelle Everill | NEW YORK, Sept. 3, 2024 /PRNewswire/ -- ProofPilot, the leading Clinical Experience Platform (CXP) that centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience, welcomes the addition o... |
| 10.07.2024 | Antonin (Tony) de Fougerolles appointed as new Chair of etherna | Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam
Will take an active role in expanding partnerships with biopharma
Integrated partnership offering to customers remai... |
| 30.04.2024 | Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including... | The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance
Medison, the creator and leader of the multi-regional partnership category, will utilize its unique... |
| 07.03.2024 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY | - |
| 05.03.2024 | Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when add... | - |
| 26.10.2023 | 米国Alnylam Pharmaceuticals社が9 月6 日に配信: トランスサイレチン型家族性アミロイドポリニューロパチーの患者さんへのホリスティックケアを提唱する提言... | RNAi 治療のリーディングカンパニーであるAlnylam Pharmaceuticals社の日本法人Alnylam Japan株式会社（本社：東京都千代田区、代表取締役社長 岡田 裕、以下「アルナイラム」）は、希少・難治性疾患に対する創薬研究や治療薬の提供とともに、これらの疾患とともに生きる患者さんが少しでもより良い日常生活を送ることができるように、疾患に関する認知・理解の促進、治療に関するサポート、その他に寄与する活動にも取り組んでいます※。
本日は、毎年10月26日に... |
| 09.03.2023 | Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics | ZUG, Switzerland, March 9, 2023 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly inn... |
| 07.02.2023 | CRISPR pioneer Feng Zhang's secretive gene-editing startup has hired ex-Alnylam leaders as CEO and chair | Feng Zhang founded Aera Therapeutics in 2021 based off his gene-editing delivery research. Susan Walsh/AP This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
The gene-editing start... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | After 17 years helping Alnylam steer control of buzzy but unproven science they promised could change medicine, president Barry Greene is leaving the RNAi biotech just as that technology is beginning to hit prime time.
Leaving to “pursue ou... |
| 13.04.2020 | Alnylam To Receive $2 Billion Financing from Blackstone | Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a Cambridge, MA-based RNAi therapeutics company, is to receive an up to $2 billion financing from Blackstone (NYSE: BX).
The package will support Alnylam’s advancement of innovative RNA interfer... |
| 13.04.2020 | Alnylam scores $2B from Blackstone to propel pipeline prospects
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | With two approved drugs and a third on the way, Alnylam secured some much-needed capital to keep its RNAi pipeline rolling. Blackstone will provide Alnylam with up to $2 billion in exchange for a 50% cut of the royalties on its Novartis-par... |
| 13.04.2020 | Alnylam scores $2B from Blackstone to propel pipeline prospects | With two approved drugs and a third on the way, Alnylam secured some much-needed capital to keep its RNAi pipeline rolling. Blackstone will provide Alnylam with up to $2 billion in exchange for a 50% cut of the royalties on its Novartis-par... |
| 10.04.2020 | The coronavirus sneaks into cells through a key receptor. Could targeting it lead to a treatment? | Nearly 20 years ago, when a different coronavirus struck, Michael Farzan and his team figured out how it was getting into human cells: targeting a specific receptor called ACE2 found on certain cells.
During this year’s ongoing novel corona... |
| 14.02.2015 | Arcturus emerging as a strong player in RNA therapeutics space | The company’s data has advanced to show that this siRNA approach not only works in primates, but has demonstrated longevity in its efficacy. Here’s how Payne describes how it works:
“Imagine a spigot spinning off mutated proteins it’s not s... |
| 03.06.2013 | RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round | “After we finalize licensing agreements and achieve in-vivo proof-of-concept with our IP, then we will be armed with the tools and data necessary to raise substantial money to take us forward to the clinic,” Payne said.
The technique of RNA... |
| 15.11.2010 | Nonprofit takes risk out of device development for Medtronic | For companies like Medtronic Inc. (NYSE:MDT), developing breakthrough technologies to treat untreatable diseases can be expensive and have little promise of financial returns.
The risk is high enough for — even companies as well-resourced a... |
| 12.11.2010 | Medtronic’s research partnership: a roadmap to the future? | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 02.09.2009 | Akebia adds Dr. Victor Dzau, Duke Health CEO, to board of directors | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 23.05.2008 | Lies, Damned Lies, and Statistics: The Definitive Rundown on New England Biotech | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
It’s official: 2007 rocked for New England biotech. Whether you look at IPOs, mergers, or venture activity, the region is consistently among the nation’s leaders. And on a per... |
| 12.07.2007 | Roundup: Biogenerics bill in limbo, clashing data on health IT benefits, the RNAi boom, and more | House-Senate confrontation set over biogenerics — Late last month, a key group of senators reached agreement on legislative provisions that would authorize copycat versions of biotech drugs, which are typically complex proteins manufactured... |
| - | Alnylam gets $2B funding boost from Blackstone to develop drug pipeline | Alnylam Pharmaceuticals CEO John Maraganore
A large private equity firm is pumping $2 billion into a biotechnology company to help it develop drugs that treat diseases by silencing genes.
Cambridge, Massachusetts-based Alnylam Pharmaceutica... |
| - | RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round | An RNAi delivery startup that’s been keeping a low profile has emerged with the announcement of a completed seed funding round and acceptance to Janssen Labs.
MedCity News learned in April that Arcturus Therapeutics was raising a $1.3 milli... |
| - | Medtronic’s research partnership: a roadmap to the future? | For companies like Medtronic Inc. (NYSE:MDT), developing breakthrough technologies to treat untreatable diseases can be risky and expensive. That’s why it’s nice to have a little bit of help from your friends.
Actually, make that a lot of h... |
| - | Akebia adds Dr. Victor Dzau, Duke Health CEO, to board of directors | CINCNNATI, Ohio — Dr. Victor Dzau, the president and CEO of the Duke University Health System, has joined the board of directors of Akebia Therapeutics.
This adds heavyweight talent to some significant fund-raising by Akebia. Last month it ... |
| - | Arcturus emerging as a strong player in RNA therapeutics space | With a fast-growing pipeline of siRNA and mRNA drugs, San Diego startup Arcturus Therapeutics is poised join the ranks of more established RNA-based drug companies like Alnylam and Moderna Therapeutics.
It’s welcome timing, as the market’s ... |
| - | Alnylam sues Moderna & Pfizer, claiming Covid-19 vaccines infringe lipid patent | RNA therapies pioneer Alnylam Pharmaceuticals is suing both Moderna and Pfizer, claiming that their messenger RNA Covid-19 vaccines infringe on a patented technology key to the way these products are delivered in the body and break down wit... |
